Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient

被引:63
作者
Capone, D. [1 ]
Tarantino, G. [2 ]
Gentile, A. [1 ]
Sabbatini, M. [3 ]
Polichetti, G. [1 ]
Santangelo, M. [4 ]
Nappi, R. [3 ]
Ciotola, A. [3 ]
D'Alessandro, V. [4 ]
Renda, A. [4 ]
Basile, V. [1 ]
Federico, S. [3 ]
机构
[1] Univ Naples Federico 2, Sch Med, Clin Pharmacol Unit, Dept Neurosci, I-80131 Naples, Italy
[2] Univ Naples Federico 2, Sch Med, Sect Hepatol Internal Med, Dept Clin & Expt Med, I-80131 Naples, Italy
[3] Univ Naples Federico 2, Sch Med, Dept Systemat Pathol Nephrol & Renal Transplantat, I-80131 Naples, Italy
[4] Univ Naples Federico 2, Sch Med, Gen Thorac & Vasc Surg Dept, I-80131 Naples, Italy
关键词
drug metabolism; tacrolimus; therapeutic drug monitoring; voriconazole; HUMAN LIVER-MICROSOMES; DRUG-INTERACTIONS; AGENTS; PHARMACOKINETICS; INHIBITION;
D O I
10.1111/j.1365-2710.2009.01070.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P>Infection occurs frequently in the organ transplant recipients during the post-transplant period because of immunosuppression. Therefore, prophylactic antimicrobial agents are often used. The azole antifungals, widely prescribed prophylactically, are known to have many drug-drug interactions. This report presents a case of drug-drug interaction between voriconazole and tacrolimus in a kidney transplant recipient. Voriconazole treatment led to a dramatic increase in tacrolimus concentration that required its discontinuation in spite of the manufacturer's guidelines that recommend a reduction of tacrolimus dosage by one-third. The present drug-drug interaction can be attributed to a strong inhibitory effect on cytochrome P450-3A4 activity by voriconazole. When voriconazole and tacrolimus are coadministered, close monitoring of tacrolimus blood levels is recommended as the rule-of-thumb reduction of tacrolimus dose by one-third may not be satisfactory.
引用
收藏
页码:121 / 124
页数:4
相关论文
共 20 条
[1]   Metabolic drug-drug interactions of the azole antifungai drugs [J].
Billaud, Eliane M. .
JOURNAL DE MYCOLOGIE MEDICALE, 2007, 17 (03) :168-176
[2]   Tacrolimus pharmacokinetics in BMT patients [J].
Boswell, GW ;
Bekersky, I ;
Fay, J ;
Wingard, J ;
Antin, J ;
Weisdorf, D ;
Maher, R ;
Fitzsimmons, W ;
Nash, R .
BONE MARROW TRANSPLANTATION, 1998, 21 (01) :23-28
[3]   Therapeutic monitoring of tacrolimus in pediatric and adult transplanted patients [J].
Capone, D ;
Gentile, A ;
Vajro, P ;
Stanziale, P ;
Imperatore, P ;
De Silva, C ;
Pellegrino, T ;
Basile, V .
JOURNAL OF CHEMOTHERAPY, 1998, 10 (02) :176-178
[4]   Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient [J].
Capone, D ;
Gentile, A ;
Imperatore, P ;
Palmiero, G ;
Basile, V .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (10) :1124-1125
[5]   Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients [J].
Christiaans, M ;
van Duijnhoven, E ;
Beysens, T ;
Undre, N ;
Schäfer, A ;
van Hooff, J .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) :1271-1273
[6]   Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein [J].
Cummins, CL ;
Wu, CY ;
Benet, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :474-489
[7]   Voriconazole in the treatment of invasive mold infections in transplant recipients [J].
Fortún, J ;
Martín-Dávila, P ;
Sánchez, MA ;
Pintado, V ;
Alvarez, ME ;
Sánchez-Sousa, A ;
Moreno, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (07) :408-413
[8]  
GRENIER FC, 1991, TRANSPLANT P, V23, P2748
[9]  
IWASAKI K, 1993, RES COMMUN CHEM PATH, V82, P209
[10]   Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation [J].
Kawazoe, Hitoshi ;
Takiguchi, Yoshiharu ;
Tanaka, Hiroaki ;
Fukuoka, Noriyasu ;
Ohnishi, Hiroaki ;
Ishida, Toshihiko ;
Houchi, Hitoshi .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (12) :2528-2531